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The interaction of dopaminergic and cholinergic neurotransmission in, e.g. 
Parkinson’s disease has been well established. Here, D2 receptor antagonists were 
used to assess changes in [18F]-FEOBV binding to the vesicular acetylcholine 
transporter (VAChT) in rodents using positron emission tomography (PET). After 
pretreatment with either 10 mg/kg haloperidol, 1 mg/kg raclopride, or vehicle, 90-
min dynamic PET scans were performed with arterial blood sampling. The net 
influx rate (Ki) was obtained from Patlak graphical analysis, using a metabolite-
corrected plasma input function and dynamic PET data. [18F]-FEOBV concentration 
in whole-blood or plasma, and the metabolite-corrected plasma input function were 
not significantly changed by the pretreatments (adjusted p > 0.07, Cohen’s d 0.28-
1.89) while the area-under-the-curve (AUC) of the parent fraction of [18F]-FEOBV 
was significantly higher after haloperidol treatment (adjusted p = 0.022, Cohen’s 
d = 2.51) than in controls. Compared to controls, the AUC of [18F]-FEOBV, 
normalized for injected dose and body weight, was nonsignificantly increased in 
the striatum after haloperidol (adjusted p = 0.4, Cohen’s d = 1.77) and raclopride 
(adjusted p = 0.052, Cohen’s d = 1.49) treatment, respectively. No changes in the 
AUC of [18F]-FEOBV were found in the cerebellum (Cohen’s d 0.63-0.74). 
Raclopride treatment nonsignificantly increased Ki in the striatum 1.3-fold 
compared to control rats (adjusted p = 0.1, Cohen’s d = 1.1) while it reduced Ki in 
the cerebellum by 28% (adjusted p = 0.0004, Cohen’s d = 2.2) compared to control 
rats. Pretreatment with haloperidol led to a nonsignificant reduction in Ki in the 
striatum (10%, adjusted p = 1, Cohen’s d = 0.44) and a 40-50% lower Ki than 
controls in all other brain regions (adjusted p < 0.0005, Cohen’s d = 3.3–4.7). The 
changes in Ki induced by the selective D2 receptor antagonist raclopride can in part 
be quantified using [18F]-FEOBV PET imaging. Haloperidol, a nonselective D2 / σ 
receptor antagonist, either paradoxically decreased cholinergic activity or blocked 
off-target [18F]-FEOBV binding to σ receptors. Hence, further studies evaluating the 





Traditionally, Parkinson’s disease is viewed as a neurodegenerative disorder that 
is characterized by motor impairments, including slowness of movement, muscle 
stiffness, and tremor. These motor symptoms result from the degeneration of 
dopaminergic neurons in the substantia nigra and the consequent deficiency of 
dopamine in brain regions that receive dopaminergic input from this brain region1, 
such as the striatum. It is now evident that Parkinson’s disease also involves 
nonmotor symptoms that can be explained by the degeneration of multiple 
neurotransmitter systems,2,3 including the cholinergic system. Loss of cholinergic 
neurons has been reported in Parkinson’s disease and has been thought to play a 
significant role in cognitive decline and motor symptoms such as tremor.4,5  
To gain more insight into the relation between dopaminergic and cholinergic 
neurotransmission in Parkinson’s disease, the noninvasive imaging technique 
positron emission tomography (PET) can play an important role. [18F]-FEOBV, a 
benzovesamicol analog, is a PET ligand that binds allosterically to the vesicular 
acetylcholine transporter (VAChT).6–8 VAChT is expressed in presynaptic 
cholinergic neurons and transports acetylcholine into synaptic vesicles. While 
VAChT is not a direct marker of acetylcholine synthesis or release, it has been 
shown that the expression of VAChT can be used to study cholinergic neurons.9,10 
For example, clinical studies using [18F]-FEOBV have revealed changes in the 
cholinergic system in patients with Parkinson’s disease.11,12  
Using microdialysis in rodents, it has been shown that the turnover of acetylcholine 
and its release into the synaptic cleft is increased after blocking of the dopamine D2 
receptors.13–15 Additionally, an increased uptake or binding of benzovesamicol 
radioligands in the striatum has been reported after the block of D2 receptors.16–18 
While the exact mechanisms leading to the increased binding of benzovesamicols 
following D2 receptor block are unknown, it has been suggested that changes in 
the vesamicol binding site of the VAChT are dependent on cholinergic activity, e.g. 
increased acetylcholine release.16 Here, we aimed to determine if acute blocking of 
the dopamine D2 receptors would lead to increased accumulation of [18F]-FEOBV 
as a measure of cholinergic activity. For this purpose, we chose the selective 
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dopamine D2/D3 receptor antagonist raclopride and the less selective D2 receptor 
antagonist haloperidol which have previously been used in this context and 
estimated cholinergic activity as measured by the net influx rate (Ki) estimated by 
Patlak graphical analysis.16–19  
Experimental Section 
Experimental Animals 
The experiments were approved by the National Committee on Animal 
Experiments (CCD:AVD105002015166) and the Institutional Animal Care and Use 
Committee of the University of Groningen (IvD:15166-01-003). Male Wistar rats 
(n = 18, Hsd/Cpb:WU, aged 12.2 ± 2.3 weeks, 364 ± 33 g) were obtained from 
Envigo (The Netherlands) and housed in groups in humidity and temperature-
controlled (21 ± 2 ⁰C) rooms with a 12 h/12 h light/dark cycle (lights on at 7 a.m.). 
Water and standard laboratory chow were supplied at libitum. After arrival the rats 
were acclimatized for at least seven days and then randomly divided in three 
groups treated with either vehicle (control, n = 6), 10 mg/kg haloperidol 19 (n = 6), 
or 1 mg/kg raclopride 20 (n = 6). The PET scans were executed between 1 and 5 
p.m. No blinding of the investigators was possible during the experiment, but the 
data analysis was automated and, hence, independent of the operator. 
PET Imaging 
The rats were anesthetized with isoflurane (5% for induction, 1 - 2.5% for 
maintenance) in 95% oxygen and eye salve was applied to prevent dehydration of 
the eyes. Rats were then injected intraperitoneally with 100 µL DMSO (control), 10 
mg/kg haloperidol or 1 mg/kg raclopride in 100 µL DMSO at 52 ± 10 min (range 44-
80 min) before injection of [18F]-FEOBV. One cannula was placed in the tail vein for 
injection of [18F]-FEOBV and a second in the femoral artery for arterial blood 
sampling. A dedicated small animal PET scanner (Focus 220 MicroPET, Siemens 
Healthcare, USA) was used and two rats were scanned simultaneously. For 
attenuation correction, a transmission scan with a 57Co point source was performed 
before each emission scan. During the PET scan, the heart rate and oxygen 
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saturation were monitored and heating pads were used to maintain the body 
temperature of the rats between 37 and 38°C. [18F]-FEOBV (28 ± 8 MBq, molar 
activity: > 300000 GBq/mmol) was injected over 1 min at a rate of 1 mL/min via an 
infusion pump and a dynamic PET scan of 90 min was started simultaneously with 
injection. Synthesis of [18F]-FEOBV was performed according to Mulholland et al. 
with adjustments to local infrastructure.21  
An attenuation-weighted 2-dimensional ordered subset expectation-maximization 
algorithm (OSEM2D, 4 iterations, 16 subsets) following Fourier rebinning was used 
for iterative reconstruction of the list mode data binned into 24 frames (6 x 10, 
4 x 30, 2 x 60, 1 x 120, 1 x 180, 4 x 300, 6 x 600 s). The data were normalized, and 
corrected for scatter, attenuation and decay. The resulting image matrix was 256 x 
256 x 95 with a slice thickness of 0.796 mm and a pixel width of 0.633 mm. 
One rat in the haloperidol treatment group died 54 min after the injection of [18F]-
FEOBV and was excluded from the analysis. 
Arterial Blood Sampling and Metabolite Analysis 
At approximately 10, 20, 30, 40, 50, 60, 90 s and 2, 3, 5, 7.5, 10, 15, 30, 60, and 
90 min after [18F]-FEOBV injection blood samples (0.10-0.13 mL each) were drawn 
from the femoral artery. The same volume of heparinized saline was injected after 
collection of each blood sample to compensate for blood loss. Plasma was 
obtained by centrifugation of whole-blood for 5 min at 30000 g. An automated well-
counter (Wizard2480, PerkinElmer, USA) was used to measure radioactivity 
(decay corrected) in 25 µL of whole-blood and 25 µL of plasma. 
Metabolite analysis was performed for all plasma samples obtained between 1 and 
90 min.19 After acetonitrile (50 µL) was added to each sample, the samples were 
vortexed and centrifuged (300 g for 8 min). A 1 to 2 µL portion of the supernatant 
from each sample were pipetted onto a silica gel 60 F254 plate (Merck, Germany), 
and the elution was performed with a mixture of hexane/dichloromethane/diethyl 
ether/triethylamine (2.3/1/1/0.2). A phosphor storage screen (PerkinElmer, USA) 
was exposed overnight to the eluted silica plates and scanned the next day using a 
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Cyclone (PerkinElmer, USA) phosphorescence imager. OptiQuant software 3 was 
used to obtain the percentage of intact tracer for correction of the plasma input 
curve. 
PET Data Analysis 
PET data analysis was performed using PMOD 3.9 software. Each individual PET 
image was automatically coregistered to a [18F]-FEOBV template.22 A volume of 
interest (VOI) atlas, containing frontal cortex, remainder of the cortex (referred to 
as “cortex”), striatum, thalamus, hypothalamus, hippocampus, brainstem, and 
cerebellum, was then placed on each coregistered PET image. For each individual 
rat, time-activity curves (in kBq/mL) were generated for each VOI. Based on 
previous analysis from our laboratory, irreversible plasma input models were best 
suited for [18F]-FEOBV quantification in rats. Irreversible plasma input models 
estimate the net influx rate (Ki = K1*k3/(k2+k3)) which estimates the irreversible 
binding but also the net influx of the radioligand. In this study, Patlak graphical 
analysis showed a lower variation of the net influx rate compared to the irreversible 
two-tissue compartment model (2TCM). Ki from Patlak graphical analysis was 
estimated with a stretch time of 10 min, whole-blood, and metabolite-corrected 
plasma input.23  
Statistical Analysis 
Statistical analysis was performed using SPSS 23. The area under the curve 
(AUC) was determined for the parent fraction, the plasma (with or without 
correction for metabolites) and whole-blood time-activity curves and the striatal and 
cerebellar time-activity curves. The time-activity curves for plasma, whole-blood, 
and brain regions were normalized to standardized uptake values (SUV = tissue 
activity concentration/(injected dose/body weight)). Differences in AUC between 
treatments were assessed using one-way analysis of variance (ANOVA). Posthoc 
analysis was performed using Bonferroni correction for multiple comparisons 
between control and treatments and the adjusted p-values are given. 
For the Ki obtained from PET imaging, the differences between the three groups 
were assessed using a generalized estimating equations (GEE) with treatment as 
Chapter 4 
 98 
between-group factor, brain region as within-subject factor and treatment × brain 
region as the interaction. Posthoc tests for differences between treatments were 
performed for each brain region and corrected for multiple comparisons using the 
Bonferroni method. GEE was used to assess differences between the three groups 
while accounting for intraindividual differences and repeated measures, i.e. the 
dependence of brain regions in each rat (within-subject). Cohen’s d was calculated 
for each treatment group using the means and pooled standard deviation of the 
control and treatment group.24 
Differences were deemed statistically significant with p < 0.05 (adjusted for multiple 
comparison using Bonferroni correction if necessary). Effect sizes with Cohen’s d > 
0.5, 0.8, 1.2 and 2.0 were considered medium, large, very large and huge, 
respectively.25 
One rat of the control group showed an exceptionally large value for Ki as obtained 
by Patlak graphical analysis in all brain regions (> 1.5 x interquartile range) and 
was excluded from the analysis. 
Results 
Tracer Kinetics and Metabolism 
The time-activity curves of [18F]-FEOBV were analyzed for two brain regions 
representing the highest (striatum) and lowest (cerebellum) uptake of [18F]-FEOBV. 
[18F]-FEOBV showed an initial high uptake in both regions, with the highest [18F]-
FEOBV uptake in the striatum at approximately 3 to 4 min after injection in control 
and haloperidol treated rats and at 6 to 8 min in rats treated with raclopride (Figure 
1). The area-under-the-curve (AUC) of the striatal time-activity curve tended to be 
higher in haloperidol (Cohen’s d = 1.77) and raclopride treated rats (Cohen’s d = 
1.49) when compared to control rats, but these differences were not statistically 
significant (F(2,15) = 3.7, p = 0.053). In the cerebellum, the highest initial uptake of 
[18F]-FEOBV was found between 1 and 3 min, with a 9% and 14% higher uptake in 
haloperidol and raclopride treated rats, respectively, than in control rats.  




Figure 1 Uptake of [18F]-FEOBV in the brain of control rats and rats pretreated with 10 
mg/kg haloperidol or 1 mg/kg raclopride. The net influx rate (Ki) images of representative 
rats from each group are shown (A) as well as the time-activity curves of the striatum and 
cerebellum for all rats in each group (mean + SD) (B). 
 
Figure 2 Time-activity curves of [18F]-FEOBV uptake in whole-blood (A) and plasma (B), 
and the parent fraction of [18F]-FEOBV (C) for control rats and rats pretreated with 10 mg/kg 
haloperidol or 1 mg/kg raclopride (mean + SD). 
Chapter 4 
 100 
On average the AUC of the cerebellar time-activity curve tended to be increased in 
raclopride (Cohen’s d = 0.74) and decreased in haloperidol treated rats (Cohen’s d 
= 0.63), but this was not statistically significant (F(2,15) = 2, p = 0.2). 
The AUC of the plasma and whole-blood time-activity curve (Figure 2) was not 
significantly changed by pretreatment with haloperidol (plasma Cohen’s d = 0.63, 
whole-blood Cohen’s d = 1.10) or raclopride (plasma Cohen’s d = 0.39, whole-
blood Cohen’s d = 0.41) compared to control rats (plasma, F(2,15) = 0.6, p = 0.5; 
whole-blood, F(2,15) = 2.3, p = 0.1). A statistically significant difference in the AUC 
of the parent fraction between the three groups was found (F(2,11) = 6, p = 0.022). 
Posthoc tests revealed a statistically significantly higher AUC of the parent fraction 
in haloperidol treated rats when compared to controls (adjusted p = 0.022, Cohen’s 
d = 2.51), while no statistically significant difference was found between the AUC of 
the parent fraction of the control and raclopride treatment groups (adjusted p = 0.6, 
Cohen’s d = 1.16). Despite a statistically significant difference in the AUC of the 
parent fraction between the haloperidol and control rats, the difference in the AUC 
of the metabolite-corrected plasma curve was not significant (F(2,15) = 3.3, p = 
0.07; haloperidol, Cohen’s d = 1.89; raclopride, Cohen’s d = 0.28). 
Net influx rate of [18F]-FEOBV  
Patlak graphical analysis revealed average Ki values ranging from 0.031 to 0.167 
mL/cm3/min for different treatment groups and brain regions. The highest Ki was 
found in the striatum, and the lowest in the cerebellum, for all three groups (Table 
1). A statistically significant effect of treatment (χ2(1,2) = 40, p < 0.0001) and brain 
region (χ2(1,7) = 691, p < 0.0001) on the Ki of [18F]-FEOBV was found, as well as a 
statistically significant interaction between treatment and brain region (χ2(1,13) = 
3475, p < 0.0001). Posthoc analysis revealed a statistically significant difference in 
Ki between control and haloperidol treated rats and between haloperidol and 
raclopride treated rats for all brain regions together (adjusted p < 0.0001), but no 
statistically significant difference was found between control and raclopride treated 
rats (adjusted p = 1). Comparison of the treatments in each individual brain region 
(Figure 3) revealed a statistically significant difference between haloperidol treated 
and control rats in brainstem, cerebellum, cortex, frontal cortex, hippocampus, 
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hypothalamus and thalamus (adjusted p < 0.0005, Cohen’s d 3.29-4.66), but not in 
striatum (adjusted p = 1, Cohen’s d 0.44) most likely due to the large variation in Ki 
(coefficient of variation 23%) in this brain region. In all other brain regions, the Ki 
was statistically significantly decreased by an average of 45 ± 3%, with the largest 
decrease of 49% to 50% in the cerebellum and hippocampus and the lowest of 
40% in the cortex. Contrarily, the only individual brain region with a significant 
difference between control and raclopride treated rats was the cerebellum 
(adjusted p = 0.0004, Cohen’s d 2.15) with a decrease in Ki of 28%. In the striatum, 
an increase in Ki of 30% was found. Despite a large effect size, this difference did 
not reach the threshold for statistical significance (adjusted p = 0.1, Cohen’s d 
1.09). In the other brain regions, Ki was found to be decreased by 8 ± 5%, but this 
effect was not statistically significant (Cohen’s d 0.06-0.97). Significant differences 
between haloperidol and raclopride treatment were found in all individual brain 
regions (adjusted p < 0.05) with an average difference in Ki of 60 ± 13% (42 to 
81%). 
 
Figure 3 Net influx rate (Ki) of [18F]-FEOBV in different brain regions for control rats and rats 
treated with 10 mg/kg haloperidol or 1 mg/kg raclopride (boxplot, box: interquartile range, 
whiskers: 1.5 x interquartile range) and adjusted p-values from posthoc comparison of 




Table 1 Net Influx Rate (Ki, [mL/cm3/min], mean ± SD) of [18F]-FEOBV in Brain Tissue in 
Control Rats and Rats Pretreated with 10 mg/kg Haloperidol or 1 mg/kg Raclopride, and the 
Effect Size (Cohen’s d) Comparing the Control Group to Each Pretreatment. 
Brain region Control (n = 5) Haloperidol (n = 5) Raclopride (n = 6) 
Ki Ki Cohen's d Ki Cohen's d 
Brainstem 0.077±0.013 0.044±0.006 3.29 0.071±0.011 0.52 
Cerebellum 0.062±0.009 0.031±0.002 4.66 0.045±0.007 2.15 
Cortex 0.074±0.010 0.044±0.007 3.41 0.069±0.010 0.49 
Frontal Cortex 0.089±0.012 0.050±0.011 3.52 0.090±0.022 0.06 
Hippocampus 0.074±0.011 0.037±0.008 3.95 0.062±0.012 0.97 
Hypothalamus 0.090±0.011 0.049±0.007 4.40 0.082±0.016 0.59 
Striatum 0.129±0.032 0.117±0.023 0.44 0.167±0.038 1.09 
Thalamus 0.079±0.012 0.044±0.008 3.36 0.073±0.013 0.49 






In the current study, we have found changes in the net influx rate of [18F]-FEOBV 
after acute treatment with D2 receptor antagonists, using PET imaging. The 
specific D2 receptor antagonist raclopride led to a statistically significant decrease 
in the net influx rate of [18F]-FEOBV in the cerebellum and nonstatistically 
significant increase of the net influx rate in the striatum. In contrast, the less 
specific D2 receptor antagonist haloperidol led to a decreased net influx rate in all 
brain regions except the striatum. Although haloperidol significantly decreased the 
metabolism of [18F]-FEOBV, treatment with either raclopride or haloperidol did not 
affect the whole-blood, plasma and the metabolite-corrected plasma input, showing 
that changes found in the net influx rate Ki were not due to hemodynamic 
differences.  
Interestingly, we found a statistically significant decrease in the net influx rate of 
[18F]-FEOBV in the cerebellum of rats treated with raclopride. Contrarily, a study by 
Efange et al. using the VAChT radioligand (+)-[125I]-MIBT in rats found no change 
in the cerebellar uptake of (+)-[125I]-MIBT after treatment with the D2 receptor 
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antagonist S-(-)-eticlopride.26 In the same study, however, a significant increase in 
the uptake of the less specific (-)-[125I]-MIBT in the cerebellum after spiperone (D2 
receptor antagonist) treatment was observed. The discrepancy between our and 
the study of Efange et al. could be related to the different D2 receptor antagonists 
used and their varying binding affinities to the D2 receptor and potential off-target 
binding.27 Additionally, Efange et al. performed ex vivo biodistribution after 3 h, 
while we determined the net influx rate of [18F]-FEOBV using Patlak graphical 
analysis using a 90-min PET acquisition. The difference in time, as well as the 
more specific quantification via PET imaging with pharmacokinetic modeling 
compared to the ex vivo distribution, could explain the differences between our 
study and the study of Efange et al. Previous studies showed only negligible 
binding of the D2 receptor antagonist raclopride in the cerebellum of rats.28,29 
Additionally, it was also determined that raclopride binding in the striatum was 
saturated at 23.5 pmol/g 28 which could suggest that the higher dose of 
approximately 3 nmol/g (1 mg/kg) of raclopride used in our study could have led to 
increased off-target binding of raclopride to serotonergic or adrenergic receptors 
and thereby facilitated the decrease in the net influx rate of [18F]-FEOBV via 
interaction with other neurotransmitters.28  
While we found a decrease in [18F]-FEOBV net influx rate in the cerebellum, the net 
influx rate and area-under-the-curve of [18F]-FEOBV in the striatum tended to be 
increased after raclopride treatment as evidenced by the large effect size found 
between control and raclopride treated rats. Ingvar et al. showed increased uptake 
of the VAChT radioligand [18F]-NEFA in the striatum of primates after raclopride or 
haloperidol treatment.16 Similarly, Efange et al. showed increased striatal uptake of 
(+)-[125I]-MIBT in rats pretreated with spiperone and S-(-)-eticlopride at 3 h after 
injection of (+)-[125I]-MIBT.17 In addition, after depletion of dopaminergic neurons in 
the rat striatum with 6-OHDA, a smaller spiperone-induced increase in (+)-[125I]-
MIBT uptake was found in the ipsilateral striatum, when compared to the 
contralateral side.26 In a more recent study, Jin et al. showed a 1.5-fold increase in 
binding of the VAChT ligand [11C]-TZ659 in striatum after treatment with S-(-)-
eticlopride.18 These findings indicate that D2 receptor antagonism results in an 
increased binding of benzovesamicol radioligands in the striatum, most likely due 
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to increased acetylcholine turnover facilitated by the antagonized D2 receptor 13–
15,30 and suggests that with lower variability of the net influx rate in the striatum a 
significant difference might have been found in our study. Hence, our study 
suggests that [18F]-FEOBV could be capable of measuring increased cholinergic 
activity in rats after treatment with the D2 receptor antagonist raclopride. 
Raclopride tended to increase the net influx rate of [18F]-FEOBV in the striatum, 
whereas, haloperidol, the other D2 receptor antagonist used in this study, 
nonsignificantly decreased the net influx rate by 10%. In fact, haloperidol 
significantly reduced the net influx rate by up to 50% in all other brain regions. 
There are several possible explanations for this result. First, the overall reduction in 
the net influx rate after haloperidol pretreatment could suggest reduced cholinergic 
activity. Nevertheless, microdialysis experiments in rats treated with haloperidol 
indicate that the opposite is the case, as an increase in acetylcholine turnover was 
observed after haloperidol treatment.15 Hence, it is unlikely that the results of our 
study can be explained by a decreased cholinergic activity due to haloperidol 
treatment. 
Second, hemodynamic changes after haloperidol treatment could have reduced 
the uptake of [18F]-FEOBV in the brain. Similar to a study by Mulholland et al., we 
used a high dose (10 mg/kg) of haloperidol. Mulholland found a reduction of [18F]-
FEOBV brain uptake and blood activity of up to 30 and 50%, respectively, when 
compared to control mice.19 They suggested that hemodynamic changes after the 
high-dose haloperidol treatment were responsible for the reduced brain uptake.19 
We found the area-under-the-curve of the [18F]-FEOBV parent fraction to be 
significantly higher compared to control rats, indicating a reduced metabolism of 
[18F]-FEOBV after haloperidol pretreatment. However, no significant differences in 
the area-under-the-curve of the whole-blood or plasma activity curve of [18F]-
FEOBV (parent and metabolite), as well as no significant changes in the 
metabolite-corrected plasma input function (parent only) between the control and 
haloperidol group, were found although the determined effect sizes were large. 
Furthermore, we found no statistically significant differences in the influx rate 
constant K1 obtained from the irreversible 2TCM between control and haloperidol 
or raclopride treated rats in any brain region (Supplemental Table 1). This suggests 
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that hemodynamic changes did not change [18F]-FEOBV delivery to the brain after 
haloperidol pretreatment in our study.  
Third, it could be possible that due to the high dose of haloperidol used in this 
study not only D2 receptors were occupied. Haloperidol binds to a variety of 
neuroreceptors, e.g. serotonergic, dopaminergic or adrenergic receptors,31 which 
could, in turn, have affected the net influx rate of [18F]-FEOBV either directly by 
changes in cholinergic neurotransmission or indirectly via the dopaminergic or 
other neurotransmitter systems. 
Another possible explanation for the reduced net influx rate of [18F]-FEOBV could 
be the blocking of σ receptors by haloperidol pretreatment. Haloperidol has been 
described as a potent σ1 receptor antagonist and σ2 receptor agonist.32 The binding 
affinity of vesamicol derivatives like [18F]-FEOBV to σ receptors has been a topic of 
dispute. Some argued that most vesamicol-based radioligands, including [18F]-
FEOBV, should not be considered for VAChT imaging because of their binding 
affinity for σ receptors.33,34 The binding affinity of (-)-FEOBV has been determined 
in vitro as 19.6 ± 1.1 nM and 209 ± 94 nM to rat VAChT and σ1 receptors, 
respectively. 33,35 A study by Mulholland et al. investigated the effect of different σ 
ligands on brain uptake and blood activity of [18F]-FEOBV in mice at three different 
time points after injection using ex-vivo biodistribution.19 Donepezil and (+)-3-PPP 
did not influence [18F]-FEOBV uptake in different brain regions or radioactivity 
levels in blood. However, donepezil is a σ1 receptor agonist as well as an 
acetylcholine esterase inhibitor, whereas haloperidol is a σ1 receptor antagonist. 
While haloperidol and (+)-3-PPP are both σ1/σ2 receptor ligands their binding 
affinities for each σ receptor are different suggesting different blocking of the σ 
receptors.32 Indeed, haloperidol led to a 36% increase of [18F]-FEOBV uptake in 
the striatum 240 min after injection, but to a reduction in whole brain uptake and 
blood activity at earlier time points in the study by Mulholland et al.19 A 
biodistribution study by Efange et al. in young rats showed reduced [125I]-MIBT 
uptake in the cerebellum (50%) and cortex (38%), in agreement with our study, and 
increased [125I]-MIBT uptake in the striatum after haloperidol treatment.17 We did 
not find a statistically significant increase in the net influx rate of [18F]-FEOBV in the 
striatum, nevertheless, as mentioned above the different time of assessment as 
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well as quantification methods, i.e. PET imaging with pharmacokinetic modeling 
compared to ex vivo biodistribution, could explain these inconsistencies.  
Further indication for binding of [18F]-FEOBV to σ receptors could be the correlation 
of the σ receptor expression pattern with the reduced [18F]-FEOBV net influx rate 
we found in our study after the haloperidol pretreatment. In the brain, σ receptors 
are found almost equally in most brain regions, with lower expression in the 
striatum and the highest expression in the brainstem.36–38 This partly agrees with 
the decreased [18F]-FEOBV net influx rate we found after haloperidol treatment. 
However, while the lowest decrease of the net influx rate was found in the striatum 
(10%), the largest reduction of approximately 50% was found in the cerebellum 
and hippocampus compared to the brainstem with 43%. This suggests that the 
decreased net influx rate partly follows the expression of σ receptors in the brain. 
Nevertheless, while the binding affinity of [18F]-FOEBV to σ1 receptors in rats has 
been determined as approximately 200 nM, it was recently shown that its binding 
affinity is approximately 10-fold lower in humans (2275 nM).39 Thus, it is likely that 
the suggested binding of [18F]-FEOBV to σ1 receptors in rats, if any, will not affect 
imaging of VAChT in humans. When using haloperidol as a D2 receptor antagonist 
its binding to other neuroreceptors should be considered, especially in studies 
using [18F]-FEOBV. Additionally, it would be of interest to study the effect of a 
dopamine D2 receptor agonist on [18F]-FEOBV binding, in comparison to the effect 
of raclopride. 
Lastly, it has been shown that isoflurane anesthesia decreases the release of 
acetylcholine in several brain regions, including striatum and cortex, in a dose-
dependent manner.40,41 Isoflurane is a widely used anesthetic in PET imaging 
studies in rodents which, at least for now, cannot be omitted during the procedure. 
As all rats in this study were treated with approximately the same dose of 
isoflurane a constant bias between the control and treatment groups can be 
assumed. Furthermore, the increase in [18F]-FEOBV net influx rate in the striatum 
after treatment with raclopride suggests increased cholinergic activity after 
treatment, even if isoflurane inhibits the release of acetylcholine. This was also 
confirmed by biodistribution studies where mice were only anesthetized for short 
periods of time and using different anesthetics.17,19 Hence, it is very unlikely that 
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the reduced [18F]-FEOBV net influx rate after haloperidol treatment was caused by 
isoflurane anesthesia. Furthermore, our study shows that acute changes in 
cholinergic activity can be evaluated using [18F]-FEOBV even under isoflurane 
anesthesia. 
Conclusion 
In the present study, we showed that changes in cholinergic activity after treatment 
with the selective D2 receptor antagonist raclopride and the nonselective D2 
receptor antagonist haloperidol can partly be quantified using [18F]-FEOBV PET 
imaging. The seemingly decreased cholinergic activity after treatment with 
haloperidol appears to be due to off-target binding of [18F]-FEOBV to σ receptors in 
rat brain. This hypothesis needs to be confirmed in further studies on the off-target 
binding of [18F]-FEOBV to σ receptors in rat brain. Such off-target binding will 
probably not occur in the human brain due to interspecies differences in the 
binding affinities of [18F]-FEOBV to σ receptors. 
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Supplemental Table 1 Influx rate constant (K1, [min-1], mean ± SD) of [18F]-FEOBV in brain 
tissue in control rats and rats pretreated with 10 mg/kg haloperidol or 1 mg/kg raclopride. K1 
was estimated using the 2-tissue compartmental model.  
Brain region Control (n = 5) Haloperidol (n = 5) Raclopride (n = 6) 
Brainstem 0.505±0.069 0.494±0.124 0.525±0.139 
Cerebellum 0.514±0.072 0.494±0.132 0.498±0.146 
Cortex 0.377±0.059 0.367±0.095 0.387±0.134 
Frontal Cortex 0.421±0.058 0.409±0.101 0.443±0.140 
Hippocampus 0.421±0.059 0.430±0.102 0.433±0.139 
Hypothalamus 0.471±0.062 0.453±0.108 0.497±0.132 
Striatum 0.428±0.076 0.418±0.095 0.451±0.142 
Thalamus 0.508±0.084 0.498±0.125 0.526±0.174 
K1 in min-1 
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